Avexitide
A GLP-1 receptor antagonist, also known as exendin 9-39, now in Phase 3 for post-bariatric hypoglycemia.
Also referenced as: Exendin 9-39
Also appears in: Other
This compound has a genuine development or study trail, but it is not an approved routine drug.
Primary lane: Hormone. Also surfaces under Other for browsing and discovery.
Exendin 9-39
No FDA label signal · 56 trials · 524 PubMed results
What avexitide is
Avexitide is a GLP-1 receptor antagonist better known in some research contexts as exendin 9-39.
Why it matters
Most peptide discussions focus on GLP-1 agonists that increase satiety and promote weight loss. Avexitide matters because it sits on the opposite side of that signaling story and is being developed for post-bariatric hypoglycemia.
Regulatory context
Avexitide is not FDA approved, but it has progressed into Phase 3 development.
Practical reading note
This page helps balance the library: not every clinically relevant peptide in metabolic medicine is trying to increase GLP-1 activity.